Lamepro

Netherlands Acquired By PharmaNovia
Pharmaceutical products for multiple disease treatments are provided.

About Lamepro

Lamepro is a Healthcare company based in Netherlands, and was acquired by PharmaNovia in March 2022. Pharmaceutical products for multiple disease treatments are provided. Its focus areas include Diversified Pharmaceuticals.

Company details

Pharmaceutical products targeted at treatments for various diseases are distributed by Lamepro, operating within the healthcare sector in the Netherlands. Focus is placed on supplying medications to support medical practices across multiple therapeutic categories. Activities encompass procurement, storage, and delivery of pharmaceuticals, with emphasis on regulatory compliance in the European market. The companys domain, lamepro.nl, facilitates online access to its catalog and services.

  • Headquarters Netherlands
  • Stage Acquired
  • Sectors
    Healthcare
  • Website lamepro.nl
  • Acquired by PharmaNovia (Mar 2022)
Key Metrics

Investors in Lamepro

Lamepro has secured backing from 1 investor. Prominent investors backing the company include PharmaNovia.

All
InvestorDescriptionFounded YearDomainLocation
Generic oncology products and antibiotics are manufactured in Copenhagen.
2003pharmanovia.comCopenhagen, Denmark
Premium access

Investor details for Lamepro

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Lamepro

Premium access

Complete news archive for Lamepro

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Lamepro

Lamepro is headquartered in Netherlands.

Pharmaceutical products targeted at treatments for various diseases are distributed by Lamepro, operating within the healthcare sector in the Netherlands. Focus is placed on supplying medications to support medical practices across multiple therapeutic categories. Activities encompass procurement, storage, and delivery of pharmaceuticals, with emphasis on regulatory compliance in the European market. The companys domain, lamepro.nl, facilitates online access to its catalog and services.

Lamepro has 1 investor. Key investors include PharmaNovia.

Yes. Lamepro was acquired by PharmaNovia in March 2022.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available